PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer

Although the MAPK pathway is aberrantly activated in triple-negative breast cancers (TNBCs), the clinical outcome of MEK-targeted therapy is still poor. Through a genome-wide CRISPR-Cas9 library screening, we find that inhibition of PSMG2 sensitizes TNBC cells BT549 and MB468 to the MEK inhibitor AZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xueyan, Yu, Jing, Liu, Xiaowei, Luo, Dan, Li, Yanchu, Song, Linlin, Jiang, Xian, Yin, Xiaomeng, Wang, Yan, Chai, Li, Luo, Ting, Jing, Jing, Shi, Hubing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512673/
https://www.ncbi.nlm.nih.gov/pubmed/36099919
http://dx.doi.org/10.1016/j.xcrm.2022.100741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512673/
https://www.ncbi.nlm.nih.gov/pubmed/36099919
http://dx.doi.org/10.1016/j.xcrm.2022.100741

Ejemplares similares